Managers / Q4 2021 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $882M in U.S.-listed holdings across 14 positions for Q4 2021.
Its largest position, SPRO, represents 9.0% of the portfolio.
Compared with Q3 2021, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 53.9% · $475M
- Common Stock · 37.8% · $334M
- Other · 6.8% · $60M
- ADR · 1.5% · $13M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF TR TR | NEW | +1.00M | 1.00M | +$475M | $475M |
| MERUS N V | NEW | +896.5K | 896.5K | +$29M | $29M |
| XBISPDR S&P BIOTECH ETF TR | SOLD OUT | −1.00M | 0 | −$126M | $0 |
| DICERNA PHARMACEUTICALS INC | SOLD OUT | −2.46M | 0 | −$50M | $0 |
| ARVNARVINAS INC | ADDED | +208.7K | 563.5K | +$17M | $46M |
| QUREUNIQURE NV | TRIMMED | −643.3K | 676.2K | −$28M | $14M |
| FDMT4D MOLECULAR THERAPEUTICS IN | ADDED | +410.0K | 1.51M | +$3M | $33M |
| ARWRARROWHEAD PHARMACEUTICALS IN | ADDED | +172.5K | 700.4K | +$13M | $46M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SPROSPERO THERAPEUTICS INChistory → | COM | 9.01% | $79M | 4.96M |
| 2 | BLUEPRINT MEDICINES CORP | COM | 7.84% | $69M | 645.5K |
| 3 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 5.27% | $46M | 700.4K |
| 4 | ARVNARVINAS INChistory → | COM | 5.25% | $46M | 563.5K |
| 5 | RGNXREGENXBIO INChistory → | COM | 3.76% | $33M | 1.01M |
| 6 | FDMT4D MOLECULAR THERAPEUTICS INhistory → | COM | 3.76% | $33M | 1.51M |
| 7 | MERUS N V | COM | 3.23% | $29M | 896.5K |
| 8 | AMRYT PHARMA PLC | SPONSORED ADS | 2.01% | $18M | 1.64M |
| 9 | QUREUNIQURE NVhistory → | SHS | 1.59% | $14M | 676.2K |
| 10 | MAGENTA THERAPEUTICS INC | COM | 1.59% | $14M | 3.16M |
| 11 | PIERIS PHARMACEUTICALS INC | COM | 1.37% | $12M | 3.20M |
| 12 | ARGXARGENX SE | SPONSORED ADR | 0.88% | $8M | 22.2K |
| 13 | GMABGENMAB A/S | SPONSORED ADS | 0.57% | $5M | 127.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.